{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T07:12:59Z","timestamp":1775805179816,"version":"3.50.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2026,2,17]]},"abstract":"<jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">Carpal tunnel syndrome (CTS) has been recognized as a potential early manifestation of systemic amyloidosis; however, its prognostic implications for cardiovascular and renal outcomes remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p xml:lang=\"en\">Using the TriNetX global federated research network, we conducted a retrospective cohort study of patients with bilateral CTS between January 2006 and December 2024. Among 221\u2009902 eligible individuals, 2099 had concomitant amyloidosis. After 1:1 propensity score matching for demographics, comorbidities, medications, and laboratory variables, 1957 matched pairs were analyzed. Outcomes included major adverse cardiovascular events, 3\u2010point major adverse cardiovascular events, heart failure, arrhythmia, dialysis initiation, and major adverse kidney events. Cox proportional hazards models and Kaplan\u2013Meier analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      Compared with patients with CTS and amyloidosis (reference group), those without amyloidosis had significantly lower risks of major adverse cardiovascular events (adjusted hazard ratio [aHR], 0.41 [95% CI, 0.28\u20130.59]), 3\u2010point major adverse cardiovascular events (aHR, 0.26 [95% CI, 0.19\u20130.35]), heart failure (aHR, 0.45 [95% CI, 0.30\u20130.64]), arrhythmia (aHR, 0.50 [95% CI, 0.35\u20130.69]), dialysis initiation (aHR, 0.51 [95% CI, 0.37\u20130.95]), and major adverse kidney events (aHR, 0.28 [95% CI, 0.25\u20130.99]; all\n                      <jats:italic toggle=\"no\">P<\/jats:italic>\n                      &lt;0.05). Kaplan\u2013Meier curves demonstrated consistently lower event\u2010free survival in the amyloidosis group. Sensitivity analyses across alternative modeling strategies yielded directionally consistent results. The median diagnostic delay from CTS to amyloidosis was 3.3\u2009years (interquartile range, 1.4\u20135.7) and was shorter in the posttafamidis era.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">Systemic amyloidosis is associated with substantially increased cardiovascular and renal risks among patients with CTS, highlighting the importance of heightened clinical vigilance and earlier recognition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/jaha.125.044104","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:25:38Z","timestamp":1770895538000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Amyloidosis in Carpal Tunnel Syndrome and 1\u2010Year Cardiovascular and Renal Outcomes: A Propensity Score\u2013Matched Cohort Study"],"prefix":"10.1161","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2064-9523","authenticated-orcid":false,"given":"Wei\u2010Ting","family":"Wang","sequence":"first","affiliation":[{"name":"Taipei Veterans General Hospital","place":["Taipei, Taiwan"]},{"name":"National Yang\u2010Ming Chiao\u2010Tung University","place":["Taipei, Taiwan"]},{"name":"National Yang\u2010Ming Chiao\u2010Tung University","place":["Taipei, Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung\u2010Pan","family":"Wang","sequence":"additional","affiliation":[{"name":"National Yang\u2010Ming Chiao\u2010Tung University","place":["Taipei, Taiwan"]},{"name":"National Yang\u2010Ming Chiao\u2010Tung University","place":["Taipei, Taiwan"]},{"name":"Taipei Veterans General Hospital","place":["Taipei, Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1376-7780","authenticated-orcid":false,"given":"Jui\u2010Yi","family":"Chen","sequence":"additional","affiliation":[{"name":"Chi\u2010Mei Hospital","place":["Tainan, Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-019-0811-z"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.5493"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.07.092"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","unstructured":"Elzinga K Khayambashi S Hahn C Mahe E Fine NM. Amyloidosis and carpal tunnel syndrome: surgical technique for extended carpal tunnel release with tenosynovium and transverse carpal ligament biopsies. 2023;11:e4757. doi: 10.1097\/GOX.0000000000004757","DOI":"10.1097\/GOX.0000000000004757"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13169"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.078915"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.04.054"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-023-06853-5"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14622"},{"key":"e_1_3_2_11_2","unstructured":"Youngstein TAB. Phenotypic and clinical outcome studies in amyloidosis and associated autoinflammatory diseases: UCL (University College London). 2019."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101619"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac119"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000366"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2091985"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.060852"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2650"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.119.045093"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhsa.2022.02.013"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhsa.2019.06.016"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-2457(02)00169-4"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2017.1313222"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-020-03912-z"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0509-RA"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2021.1950681"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/00015385.2021.1992990"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2024.02.007"},{"key":"e_1_3_2_29_2","first-page":"S107","article-title":"Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges","volume":"23","author":"Gertz MA","year":"2017","unstructured":"Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23:S107\u2013S112.","journal-title":"Am J Manag Care"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006050460"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2019.1625322"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.05.021"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.033478"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-022-00683-z"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1253\/circrep.CR-25-0092"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.125.044104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:26:19Z","timestamp":1775802379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.125.044104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,17]]}},"alternative-id":["10.1161\/JAHA.125.044104"],"URL":"https:\/\/doi.org\/10.1161\/jaha.125.044104","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"2025-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e044104"}}